Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
The small molecule macrocyclic lactone ivermectin, approved by the US Food and Drug Administration for parasitic infections, has received renewed attention in the last eight years due to its apparent exciting potential as an antiviral. It was identified in a high-throughput chemical screen as inhibi...
Main Authors: | David A. Jans, Kylie M. Wagstaff |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/9/2100 |
Similar Items
-
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic
by: Manuel Castillejos-López, et al.
Published: (2022-09-01) -
Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
by: Mudatsir Mudatsir, et al.
Published: (2020-08-01) -
Role of ivermectin in COVID-19: Wishful thinking or scientific optimism
by: Prafull Mohan, et al.
Published: (2020-01-01) -
Is Ivermectin Effective in Treating COVID-19?
by: Shuangshuang Yang, et al.
Published: (2022-06-01) -
Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols
by: L. L. M. Marques, et al.
Published: (2022-05-01)